Gilead Reports Officer Comp/Director Changes on Feb 1

TL;DR

**Gilead filed an 8-K on Feb 2nd, signaling executive compensation or leadership changes from Feb 1st.**

AI Summary

Gilead Sciences, Inc. filed an 8-K on February 2, 2024, reporting an event that occurred on February 1, 2024. This filing indicates a change in compensatory arrangements for certain officers, as well as potential departures or elections of directors or officers. While specific names and dollar amounts are not detailed in this summary filing, it signals potential shifts in executive compensation or leadership, which could impact the company's strategic direction and financial performance, making it relevant for current and prospective shareholders.

Why It Matters

Changes in executive compensation or leadership can signal strategic shifts or impact investor confidence, directly affecting the stock's perceived value.

Risk Assessment

Risk Level: medium — Without specific details on the changes, there's uncertainty regarding the impact on company stability and future performance.

Analyst Insight

Investors should monitor future Gilead filings or press releases for specific details on the reported compensatory arrangements and personnel changes to assess their potential impact on the company's strategy and financial outlook.

Key Numbers

• $0.001 — Common Stock par value per share (This is the nominal value of each share of Gilead's common stock.)

Key Players & Entities

• GILEAD SCIENCES, INC. (company) — the registrant filing the 8-K
• February 1, 2024 (date) — date of the earliest event reported in the 8-K
• February 2, 2024 (date) — date the 8-K was filed
• $0.001 (dollar_amount) — par value per share of Common Stock
• The Nasdaq Global Select Market (exchange) — where Gilead's Common Stock is registered

Forward-Looking Statements

• Gilead will provide more specific details regarding the compensatory arrangements or personnel changes in a future filing or press release. (GILEAD SCIENCES, INC.) — medium confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.001 — h registered Common Stock, par value, $0.001 per share GILD The Nasdaq Global Sele

Filing Documents

• tm244922d1_8k.htm (8-K) — 28KB
• tm244922d1_ex99-1.htm (EX-99.1) — 7KB
• tm244922d1_ex99-1img001.jpg (GRAPHIC) — 2KB
• 0001104659-24-010051.txt ( ) — 209KB
• gild-20240201.xsd (EX-101.SCH) — 3KB
• gild-20240201_lab.xml (EX-101.LAB) — 33KB
• gild-20240201_pre.xml (EX-101.PRE) — 22KB
• tm244922d1_8k_htm.xml (XML) — 3KB

02

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers (d) Appointment of a Director. On February 1, 2024, at a meeting of the Board of Directors (the "Board") of Gilead Sciences, Inc. (the "Company"), the Board increased the size of the Board from nine directors to ten directors and elected Ted W. Love, M.D., to serve on the Board, effective immediately after the close of such meeting. The Board also selected Dr. Love to serve on the Audit Committee of the Board, effective immediately upon the conclusion of the 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting"), subject to his re-election as a director by the Company's stockholders at such meeting. There is no arrangement or understanding between Dr. Love and any other persons pursuant to which Dr. Love was selected as a director, and there are no related party transactions involving Dr. Love that are reportable under Item 404(a) of Regulation S-K. Dr. Love will participate in and receive compensation for his service on the Board for the remainder of the 2023-2024 service period in accordance with the Company's standard non-employee director compensation programs, including grants to be made under the Company's 2022 Equity Incentive Plan (the "Plan"). A description of the Plan and compensation practices for non-employee directors can be found in our Definitive Proxy Statement filed with the Securities and Exchange Commission (SEC) on March 23, 2023 in connection with the Company's 2023 Annual Meeting of Stockholders. The Plan is attached as an exhibit to the Company's Current Report on Form 8-K filed with the SEC on May 5, 2022. A copy of the Company's press release announcing Dr. Love's election to the Board is attached as Exhibit 99.1 to this report.

Financial Statements and Exhibits

Financial Statements and Exhibits (d) Exhibits The following exhibit 99.1 is furnished pursuant to this Item 9.01. Exhibit Number Description 99.1 Press Release by Gilead Sciences, Inc. dated February 1, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GILEAD SCIENCES, INC. (Registrant) /s/ Deborah H. Telman Deborah H. Telman EVP, Corporate Affairs, General Counsel and Corporate Secretary Date: February 2, 2024

View Full Filing

View this 8-K filing on SEC EDGAR